Verastem VSTM
NASDAQ VSTM
$8.20 +0.22 (+2.82%)
As of: Sep 4, 2026 · 3:59 PM EDT

Verastem (VSTM) Preferred Stock Liabilities (2011 - 2024)

Verastem (VSTM) posted quarterly Preferred Stock Liabilities of $21.2 million for Q3 2024, little changed year-over-year from $21.2 million in Q4 2023, and little changed quarter-over-quarter from $21.2 million in Q2 2024.

Analysis

Verastem (VSTM) Preferred Stock Liabilities (2011 - 2024) Analysis & Trends

Verastem's Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $21.2 million for Q3 2024.

  • In Q3 2024, Preferred Stock Liabilities changed 0.0% year-over-year to $21.2 million; the TTM figure through Sep 2024 stood at $21.2 million (changed 0.0% YoY), while the FY2023 annual figure was $21.2 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q3 2024 stood at $21.2 million, roughly flat from $21.2 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $21.2 million in Q1 2023, with the low at $21.2 million in Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Verastem 814.94 Mn 678.59 Mn 36.32 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 21.16 Mn
Jun 30, 2024 21.16 Mn
Mar 31, 2024 21.16 Mn
Dec 31, 2023 21.16 Mn
Sep 30, 2023 21.16 Mn
Jun 30, 2023 21.16 Mn
Mar 31, 2023 21.16 Mn
Dec 31, 2011 68.14 Mn